22Rv1 (ATCC® CRL-2505)

Organism: Homo sapiens, human  /  Cell Type: epithelial  /  Tissue: prostate  /  Disease: carcinoma

Permits and Restrictions

View Permits

Organism Homo sapiens, human
Tissue prostate
Cell Type epithelial
Product Format frozen
Morphology epithelial
Culture Properties adherent
Biosafety Level 2

Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country.

Disease carcinoma
Storage Conditions liquid nitrogen vapor phase
Karyotype 49,XY,del(1)(p10),+i(1)(q10),der(2)t(2;4)(p13;q31)del(2)(q13q33),der(4)t(2;4)(p13;q31),t(6;14)(q15;q32),+7,+12[5]/50,idem,+3[1]
Images ATCC CRL-2505 Cell Micrograph
22Rv1 is a human prostate carcinoma epithelial cell line derived from a xenograft that was serially propagated in mice after castration-induced regression and relapse of the parental, androgen-dependent CWR22 xenograft.
Antigen Expression
prostate specific antigen (PSA)
Receptor Expression
androgen receptor
Tumorigenic Yes
Yes, forms tumors in nude mice
The cell line expresses prostate specific antigen (PSA). Growth is weakly stimulated by dihydroxytestosterone and lysates are immunoreactive with androgen receptor antibody by Western blot analysis.
Growth is stimulated by epidermal growth factor (EGF) but is not inhibited by transforming growth factor beta-1 (TGF beta- 1).
Recently , it has been shown that 22Rv1 prostate carcinoma cells produce high-titer of the human retrovirus XMRV (xenotropic murine leukemia virus-related virus).
Complete Growth Medium The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, ATCC 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum (ATCC 30-2020) to a final concentration of 10%.
Subculturing Volumes used in this protocol are for 75 cm2 flask; proportionally reduce or increase amount of dissociation medium for culture vessels of other sizes.

  1. Remove and discard culture medium.
  2. Briefly rinse the cell layer with 0.25% (w/v) Trypsin-0.53mM EDTA solution to remove all traces of serum that contains trypsin inhibitor.
  3. Add 2.0 to 3.0 mL of Trypsin-EDTA solution to flask and observe cells under an inverted microscope until cell layer is dispersed (usually within 5 to 15 minutes).
    Note: To avoid clumping do not agitate the cells by hitting or shaking the flask while waiting for the cells to detach. Cells that are difficult to detach may be placed at 37°C to facilitate dispersal.
  4. Add 6.0 to 8.0 mL of complete growth medium and aspirate cells by gently pipetting.
  5. Add appropriate aliquots of the cell suspension to new culture vessels.
  6. Incubate cultures at 37°C

Subculture Ratio: 1:3 to 1:6
Medium Renewal: Every 2 to 3 days.
Note: For more information on enzymatic dissociation and subculturing of cell lines consult Chapter 10 in Culture of Animal Cells, a manual of Basic Technique by R. Ian Freshney, 3rd edition, published by Alan R. Liss, N.Y., 1994.

Freeze medium: Complete growth medium supplemented with 5% (v/v) DMSO
Storage temperature: liquid nitrogen vapor phase
Culture Conditions
Temperature: 37°C
STR Profile
Amelogenin: X,Y
CSF1PO: 10,11
D13S317: 9,12
D16S539: 12
D5S818: 11,12,13
D7S820: 9,10,11
THO1: 6,9.3
vWA: 15,21
Population Doubling Time 40 hours
Name of Depositor JW Jacobberger

Knouf EC, et al. Multiple integrated copies and high-level production of the human retrovirus XMRV from 22Rv1 prostate carcinoma cells. J. Virol. 83: 7353-7356, 2009. PubMed: 19403664

Notice: Necessary PermitsPermits

These permits may be required for shipping this product:

  • Customers located in the state of Hawaii will need to contact the Hawaii Department of Agriculture to determine if an Import Permit is required. A copy of the permit or documentation that a permit is not required must be sent to ATCC in advance of shipment.
Basic Documentation
Other Documentation

Knouf EC, et al. Multiple integrated copies and high-level production of the human retrovirus XMRV from 22Rv1 prostate carcinoma cells. J. Virol. 83: 7353-7356, 2009. PubMed: 19403664